Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AtriCure, Inc. or Masimo Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AtriCure, Inc. and Masimo Corporation compare based on key financial metrics to determine which better meets your investment needs.

About AtriCure, Inc. and Masimo Corporation

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Latest Health Care Equipment & Supplies and AtriCure, Inc., Masimo Corporation Stock News

As of December 10, 2025, AtriCure, Inc. had a $2.0 billion market capitalization, compared to the Health Care Equipment & Supplies median of $311.5 million. AtriCure, Inc.’s stock is up 35.5% in 2025, up 5.5% in the previous five trading days and up 20.23% in the past year.

Currently, AtriCure, Inc. does not have a price-earnings ratio. AtriCure, Inc.’s trailing 12-month revenue is $518.3 million with a -5.6% net profit margin. Year-over-year quarterly sales growth most recently was 15.9%. Analysts expect adjusted earnings to reach $-0.239 per share for the current fiscal year. AtriCure, Inc. does not currently pay a dividend.

As of December 10, 2025, Masimo Corporation had a $7.5 billion market cap, putting it in the 75th percentile of all stocks. Masimo Corporation’s stock is down 14.5% in 2025, down 0.7% in the previous five trading days and down 17.72% in the past year.

Currently, Masimo Corporation does not have a price-earnings ratio. Masimo Corporation’s trailing 12-month revenue is $2.2 billion with a -26.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.2%. Analysts expect adjusted earnings to reach $5.481 per share for the current fiscal year. Masimo Corporation does not currently pay a dividend.

How We Compare AtriCure, Inc. and Masimo Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AtriCure, Inc. and Masimo Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AtriCure, Inc. and Masimo Corporation Growth Grades

Company	Ticker	Growth
AtriCure, Inc.	ATRC	C
Masimo Corporation	MASI	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

AtriCure, Inc. has a Growth Score of 48, which is Average. Masimo Corporation has a Growth Score of 70, which is Strong.

The Growth Grade Winner: Masimo Corporation

As you can clearly see from the Growth Grade breakdown above, Masimo Corporation has a more attractive growth grade than AtriCure, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Masimo Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AtriCure, Inc. and Masimo Corporation’s Quality Grades

Company	Ticker	Quality
AtriCure, Inc.	ATRC	B
Masimo Corporation	MASI	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

AtriCure, Inc. has a Quality Score of 80, which is Strong. Masimo Corporation has a Quality Score of 85, which is Very Strong.

The Quality Grade Winner: Masimo Corporation

As you can clearly see from the Quality Grade breakdown above, Masimo Corporation has a better overall quality grade than AtriCure, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Masimo Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AtriCure, Inc. and Masimo Corporation’s Momentum Grades

Company	Ticker	Momentum
AtriCure, Inc.	ATRC	B
Masimo Corporation	MASI	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

AtriCure, Inc. has a Momentum Score of 70, which is Strong. Masimo Corporation has a Momentum Score of 29, which is Weak.

The Momentum Grade Winner: AtriCure, Inc.

As you can clearly see from the Momentum Grade breakdown above, AtriCure, Inc. is considered to have stronger momentum compared to Masimo Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, AtriCure, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other AtriCure, Inc. and Masimo Corporation Grades

In addition to Momentum, Growth and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AtriCure, Inc. and Masimo Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AtriCure, Inc. or Masimo Corporation Stock?

Overall, AtriCure, Inc. stock has a Growth Score of 48, Momentum Score of 70 and Quality Score of 80.

Masimo Corporation stock has a Growth Score of 70, Momentum Score of 29 and Quality Score of 85.

Comparing AtriCure, Inc. and Masimo Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.